P
LGND icon

&Partners’s Ligand Pharmaceuticals LGND Stock Holding History

&Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$257K Buy
+814
New +$192K ﹤0.01% 2223

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

&Partners's LGND Position: Q2 2026 in Review

&Partners opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 814 shares worth $257K. The stake represents ﹤0.01% of the portfolio and ranks #2223 among its holdings.

414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • &Partners held 814 shares of Ligand Pharmaceuticals worth $257K as of Q2 2026.
  • Ligand Pharmaceuticals was a new &Partners position in Q2 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #2223 holding.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.